Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
New edition of RADAR includes review of glycopyrronium for COPD treatment

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD). [More]
Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Forest Laboratories, Inc. and Almirall, S.A. today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol. [More]
WHO report confirms air pollution as world's largest single environmental health risk

WHO report confirms air pollution as world's largest single environmental health risk

In new estimates released today, WHO reports that in 2012 around 7 million people died - one in eight of total global deaths - as a result of air pollution exposure. This finding more than doubles previous estimates and confirms that air pollution is now the world's largest single environmental health risk. Reducing air pollution could save millions of lives. [More]
COPD in older adults linked with increased risk for mild cognitive impairment

COPD in older adults linked with increased risk for mild cognitive impairment

A diagnosis of chronic obstructive pulmonary disease (COPD) in older adults was associated with increased risk for mild cognitive impairment (MCI), especially MCI of skills other than memory, and the greatest risk was among patients who had COPD for more than five years. [More]
Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

The body clock's natural rhythm could be utilized to improve current therapies to delay the onset of chronic lung diseases. [More]
Bosch Healthcare selects Brain Resource's MyBrainSolutions for use in telehealth solution

Bosch Healthcare selects Brain Resource's MyBrainSolutions for use in telehealth solution

Brain Resource has announced today that Robert Bosch Healthcare Systems, Inc. (headquarters in Palo Alto, California, USA), the market leader in evidence-based telehealth solutions, has added MyBrainSolutions to their newly launched Health Buddy Web solution for the monitoring, education, and management of people living with chronic conditions. [More]

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body's inflammatory response. [More]

Study finds significant reduction in hospital admissions with Medicare Part D prescription coverage

A new study by the Johns Hopkins Bloomberg School of Public Health and the University of Illinois at Chicago finds that Medicare Part D prescription coverage significantly reduced hospital admissions and program expenditures totaling $1.5 billion annually. [More]
New procedure offers benefits for patients with severe asthma

New procedure offers benefits for patients with severe asthma

Like millions of people, Jeannine Childs suffers from asthma. But unlike most, her asthma was debilitating. For years she struggled with wheezing, shortness of breath and fits of coughing so severe that they often landed her in the hospital. Nothing was really working – not lifestyle changes, not medications. [More]
IBM content analysis software helps identify patients at risk for developing heart failure

IBM content analysis software helps identify patients at risk for developing heart failure

IBM today announced that Virginia health system Carilion Clinic has identified 8,500 patients at risk for developing heart failure in a pilot project that could lead to early intervention and better care for these patients. [More]

Indacaterol/glycopyrronium drug combination offers added benefit for adults with COPD

​The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD). [More]

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

New research in Respirology shows that suffers of Chronic obstructive pulmonary disease (COPD) can reduce their risk of being hospitalized with severe attacks, by maintaining an exercise regime of walking between three to six kilometers a day. [More]

A non-invasive method developed to fight heart disease

Clemson University researchers have developed nanoparticles that can deliver drugs targeting damaged arteries, a non-invasive method to fight heart disease. [More]

Doctors miss opportunities to diagnose COPD at an earlier stage in primary and secondary care

A retrospective study of almost 39,000 patients shows that opportunities to diagnose chronic obstructive pulmonary disease (COPD) at an earlier stage are frequently being missed in both primary and secondary care in the UK. The findings, published in The Lancet Respiratory Medicine, reveal missed opportunities to diagnose COPD occurred in up to 85% of people. [More]

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients. [More]
Bosch Healthcare receives NCQA's Disease Management certification for HMPs

Bosch Healthcare receives NCQA's Disease Management certification for HMPs

Robert Bosch Healthcare Systems, Inc., the market leader in evidence-based telehealth solutions, today announced the that it has received certification for program design in Disease Management for 16 Health Management Programs (HMPs) that it submitted to the National Committee for Quality Assurance. [More]

Chest radiography highly predictive of pulmonary hypertension

Chest radiography is very accurate for predicting pulmonary hypertension, report researchers. [More]
Third-hand smoke as deadly as first-hand smoke

Third-hand smoke as deadly as first-hand smoke

Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke. [More]

Viewpoints: Consumers awakening to health law's 'perverse incentives;' Medicaid expansion could help Dems in mid-term elections; new 'devious tactic' in smoking

With fewer glitches to deter them, millions of Americans are now logging on to the ObamaCare health-insurance-exchange websites. When they get there, many are discovering some unpleasant surprises: [More]

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease. [More]